Rivastigmine in Mild Alzheimer's Disease, FMRI Study
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the effect of rivastigmine given as an acute dose
compared to placebo and after 1 month chronic dosing on fMRI response during a face
recognition task. Furthermore, the aim is to investigate whether fMRI response is correlated
with long term treatment effect at 6 months and 12 months.